Literature DB >> 28540626

Cross-sectional prevalence of pancreatic cystic lesions in patients with acromegaly, a single-center experience.

Yukiko Odake1, Hidenori Fukuoka2, Masaaki Yamamoto1, Yoshifumi Arisaka3, Junya Konishi4, Kenichi Yoshida1, Ryusaku Matsumoto1, Hironori Bando1, Kentaro Suda1, Hitoshi Nishizawa5, Genzo Iguchi5, Shozo Yamada6, Wataru Ogawa1, Yutaka Takahashi1.   

Abstract

PURPOSE: Acromegaly is a disease associated with an increased risk for several kinds of neoplasms including colon and thyroid cancer. Although the association between acromegaly and pancreatic neoplasms has not been elucidated, it has recently been reported that GNAS gene mutations were found in 58% of intraductal papillary mucinous neoplasms (IPMNs), which are representative pancreatic cystic lesions, suggesting a link between IPMNs and acromegaly. To assess the prevalence of pancreatic cystic lesions in patients with acromegaly, we performed a retrospective cross-sectional single institute study.
METHODS: Thirty consecutive acromegalic patients (20 females and 10 males; mean age, 60.9 ± 11.9 years) who underwent abdominal contrast-enhanced computed tomography or magnetic resonance imaging between 2007 and 2015 at Kobe University Hospital were recruited. We also analyzed the relationship between presence of pancreatic cystic lesions and somatic GNAS mutations in pituitary tumors.
RESULTS: Seventeen of 30 (56.7%) patients studied had pancreatic cystic lesions. Nine of 17 patients (52.9%) were diagnosed with IPMNs based on imaging findings. These results suggest that the prevalence of IPMNs may be higher in acromegalic patients in acromegalic patients than historically observed in control patients (up to 13.5%). In patients with pancreatic cystic lesions, the mean patient age was higher and the duration of disease was longer than in those without pancreatic cystic lesions (67.0 ± 2.3 vs. 53.0 ± 2.7 years, p < 0.001, 15.5 ± 2.4 vs. 7.3 ± 2.8 years, p = 0.04). There were no differences in serum growth hormone levels or insulin-like growth factor standard deviation scores between these two groups (21.3 ± 6.4 vs. 23.0 ± 7.4 ng/ml, p = 0.86, 6.6 ± 0.5 vs. 8.0 ± 0.6, p = 0.70). Neither the presence of somatic GNAS mutation in a pituitary tumor nor low signal intensity of the tumor in T2 weighted magnetic resonance imaging was associated with the presence of pancreatic cystic lesions.
CONCLUSIONS: These data demonstrate that old or long-suffering patients with acromegaly have a higher prevalence of pancreatic cystic lesions. Moreover, the prevalence of pancreatic cystic lesions may be increased in acromegalic patients.

Entities:  

Keywords:  Acromegaly; IPMN; Pancreatic cysts

Mesh:

Substances:

Year:  2017        PMID: 28540626     DOI: 10.1007/s11102-017-0810-1

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  24 in total

Review 1.  International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.

Authors:  Masao Tanaka; Suresh Chari; Volkan Adsay; Carlos Fernandez-del Castillo; Massimo Falconi; Michio Shimizu; Koji Yamaguchi; Kenji Yamao; Seiki Matsuno
Journal:  Pancreatology       Date:  2006       Impact factor: 3.996

2.  Hyperproliferation of PKD1 cystic cells is induced by insulin-like growth factor-1 activation of the Ras/Raf signalling system.

Authors:  E Parker; L J Newby; C C Sharpe; S Rossetti; A J Streets; P C Harris; M J O'Hare; A C M Ong
Journal:  Kidney Int       Date:  2007-03-28       Impact factor: 10.612

Review 3.  Complications of acromegaly: thyroid and colon.

Authors:  Amit Tirosh; Ilan Shimon
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

4.  American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.

Authors:  Laurence Katznelson; John L D Atkinson; David M Cook; Shereen Z Ezzat; Amir H Hamrahian; Karen K Miller
Journal:  Endocr Pract       Date:  2011 Jul-Aug       Impact factor: 3.443

5.  GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours.

Authors:  C A Landis; S B Masters; A Spada; A M Pace; H R Bourne; L Vallar
Journal:  Nature       Date:  1989-08-31       Impact factor: 49.962

6.  Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method.

Authors:  Tsuyoshi Isojima; Akira Shimatsu; Susumu Yokoya; Kazuo Chihara; Toshiaki Tanaka; Naomi Hizuka; Akira Teramoto; Ke-ita Tatsumi; Katsuhiko Tachibana; Noriyuki Katsumata; Reiko Horikawa
Journal:  Endocr J       Date:  2012-05-19       Impact factor: 2.349

Review 7.  Acromegaly pathogenesis and treatment.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2009-11-02       Impact factor: 14.808

8.  A combination of molecular markers and clinical features improve the classification of pancreatic cysts.

Authors:  Simeon Springer; Yuxuan Wang; Marco Dal Molin; David L Masica; Yuchen Jiao; Isaac Kinde; Amanda Blackford; Siva P Raman; Christopher L Wolfgang; Tyler Tomita; Noushin Niknafs; Christopher Douville; Janine Ptak; Lisa Dobbyn; Peter J Allen; David S Klimstra; Mark A Schattner; C Max Schmidt; Michele Yip-Schneider; Oscar W Cummings; Randall E Brand; Herbert J Zeh; Aatur D Singhi; Aldo Scarpa; Roberto Salvia; Giuseppe Malleo; Giuseppe Zamboni; Massimo Falconi; Jin-Young Jang; Sun-Whe Kim; Wooil Kwon; Seung-Mo Hong; Ki-Byung Song; Song Cheol Kim; Niall Swan; Jean Murphy; Justin Geoghegan; William Brugge; Carlos Fernandez-Del Castillo; Mari Mino-Kenudson; Richard Schulick; Barish H Edil; Volkan Adsay; Jorge Paulino; Jeanin van Hooft; Shinichi Yachida; Satoshi Nara; Nobuyoshi Hiraoka; Kenji Yamao; Susuma Hijioka; Schalk van der Merwe; Michael Goggins; Marcia Irene Canto; Nita Ahuja; Kenzo Hirose; Martin Makary; Matthew J Weiss; John Cameron; Meredith Pittman; James R Eshleman; Luis A Diaz; Nickolas Papadopoulos; Kenneth W Kinzler; Rachel Karchin; Ralph H Hruban; Bert Vogelstein; Anne Marie Lennon
Journal:  Gastroenterology       Date:  2015-08-04       Impact factor: 22.682

9.  Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

Authors:  Loes van Keimpema; Frederik Nevens; Ragna Vanslembrouck; Martijn G H van Oijen; Aswin L Hoffmann; Helena M Dekker; Robert A de Man; Joost P H Drenth
Journal:  Gastroenterology       Date:  2009-07-29       Impact factor: 22.682

10.  The role of diabetes in acromegaly associated neoplasia.

Authors:  Sonia Cheng; Karen Gomez; Omar Serri; Constance Chik; Shereen Ezzat
Journal:  PLoS One       Date:  2015-05-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.